ROBERT GRIGGS

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint Corticosteroids in Duchenne muscular dystrophy: major variations in practice
    Robert C Griggs
    University of Rochester, Departments of Neurology and Biostatistics, 265 Crittenden Boulevard, CU 420669, Rochester, New York, 14642, USA
    Muscle Nerve 48:27-31. 2013
  2. pmc Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies
    Daniel Platt
    School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY 14642 0669, USA
    Arch Neurol 69:527-9. 2012
  3. ncbi request reprint The current status of treatment for inclusion-body myositis
    Robert C Griggs
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Neurology 66:S30-2. 2006
  4. pmc Clinical research for rare disease: opportunities, challenges, and solutions
    Robert C Griggs
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 203, Rochester, NY 14620, USA
    Mol Genet Metab 96:20-6. 2009
  5. doi request reprint Markesbery disease: autosomal dominant late-onset distal myopathy: from phenotype to ZASP gene identification
    Robert C Griggs
    Department of Neurology, University of Rochester School of Medicine and Dentistry, 1351 Mt Hope Avenue, Suite 203, Rochester, NY 14620, USA
    Neuromolecular Med 13:27-30. 2011
  6. ncbi request reprint Inclusion body myositis
    Rabi Tawil
    Department of Neurology, University of Rochester, Rochester, New York 14642, USA
    Curr Opin Rheumatol 14:653-7. 2002
  7. ncbi request reprint Treatment of idiopathic inflammatory myopathies
    Anthony A Amato
    Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 16:569-75. 2003
  8. pmc Pivotal studies of orphan drugs approved for neurological diseases
    Jun Mitsumoto
    College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Ann Neurol 66:184-90. 2009
  9. ncbi request reprint Unicorns, dragons, polymyositis, and other mythological beasts
    Anthony A Amato
    Neurology 61:288-9. 2003

Detail Information

Publications9

  1. doi request reprint Corticosteroids in Duchenne muscular dystrophy: major variations in practice
    Robert C Griggs
    University of Rochester, Departments of Neurology and Biostatistics, 265 Crittenden Boulevard, CU 420669, Rochester, New York, 14642, USA
    Muscle Nerve 48:27-31. 2013
    ..75 mg/kg/day is of short-term efficacy in Duchenne muscular dystrophy (DMD). Subsequent efforts to standardize care for DMD indicated wide variation in corticosteroid use...
  2. pmc Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies
    Daniel Platt
    School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY 14642 0669, USA
    Arch Neurol 69:527-9. 2012
    ....
  3. ncbi request reprint The current status of treatment for inclusion-body myositis
    Robert C Griggs
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Neurology 66:S30-2. 2006
    ..However, because high-dose prednisone worsens strength while decreasing inflammation but increases amyloid accumulation, alternative targets for intervention and novel treatment strategies are needed...
  4. pmc Clinical research for rare disease: opportunities, challenges, and solutions
    Robert C Griggs
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 203, Rochester, NY 14620, USA
    Mol Genet Metab 96:20-6. 2009
    ....
  5. doi request reprint Markesbery disease: autosomal dominant late-onset distal myopathy: from phenotype to ZASP gene identification
    Robert C Griggs
    Department of Neurology, University of Rochester School of Medicine and Dentistry, 1351 Mt Hope Avenue, Suite 203, Rochester, NY 14620, USA
    Neuromolecular Med 13:27-30. 2011
    ..Thus, Markesbery disease is a zaspopathy. Other families have been identified with the same mutation and a shared haplotype indicating a founder effect...
  6. ncbi request reprint Inclusion body myositis
    Rabi Tawil
    Department of Neurology, University of Rochester, Rochester, New York 14642, USA
    Curr Opin Rheumatol 14:653-7. 2002
    ..The treatment of IBM with conventional immunosuppressive agents has been disappointing. Therapeutic approaches currently under study or consideration are beta-interferon and synthetic anabolic hormones...
  7. ncbi request reprint Treatment of idiopathic inflammatory myopathies
    Anthony A Amato
    Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Neurol 16:569-75. 2003
    ..This article reviews the results of recent therapeutic trials in dermatomyositis, polymyositis, and inclusion body myositis and suggests an approach to treating patients with inflammatory myopathy...
  8. pmc Pivotal studies of orphan drugs approved for neurological diseases
    Jun Mitsumoto
    College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Ann Neurol 66:184-90. 2009
    ..To identify design elements of clinical trials leading to US Food and Drug Administration approval of drugs for neurological diseases with and without orphan indications...
  9. ncbi request reprint Unicorns, dragons, polymyositis, and other mythological beasts
    Anthony A Amato
    Neurology 61:288-9. 2003

Research Grants19

  1. Dichlorphenamide vs Acetazolamide for Periodic Paralysis
    ROBERT GRIGGS; Fiscal Year: 2004
    ....
  2. Dichlorphenamide vs Acetazolamide for Periodic Paralysis
    ROBERT GRIGGS; Fiscal Year: 2009
    ..abstract_text> ..
  3. Novel Designs and Outcome Measures for Bench to Bedside Research on NMD
    ROBERT GRIGGS; Fiscal Year: 2007
    ..In this effort to provide new treatments for neuromuscular disease, this conference will help to further public health goals. ..
  4. Nervous System Channelopathies: Pathogenesis & Treatment
    ROBERT GRIGGS; Fiscal Year: 2007
    ..They may also offer a window for understanding common disorders likely to be caused by CNS channel mutations/dysfunction such as migraine and epilepsy. ..
  5. EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASE
    ROBERT GRIGGS; Fiscal Year: 2007
    ..Training facilities include: the General Clinical Research Center, Clinical Trials Coordination Centers, Biostatistics Department, Gorell Molecular Biology Laboratory, Center for Aging & Developmental Biology. ..
  6. Novel treatment for muscle disease: Fueling the pipeline and finding the product
    ROBERT GRIGGS; Fiscal Year: 2006
    ....
  7. Plan forTrial to find Optimum Steroid Regimen in Duchenne Muscular Dystrophy
    ROBERT GRIGGS; Fiscal Year: 2006
    ....
  8. Nervous System Channelopathies: Pathogenesis & Treatment
    ROBERT GRIGGS; Fiscal Year: 2005
    ..They may also offer a window for understanding common disorders likely to be caused by CNS channel mutations/dysfunction such as migraine and epilepsy. ..
  9. Pathogenesis and treatment of the periodic paralyses
    ROBERT GRIGGS; Fiscal Year: 2004
    ....
  10. Dichlorphenamide vs Acetazolamide for Periodic Paralysis
    ROBERT GRIGGS; Fiscal Year: 2007
    ..abstract_text> ..
  11. Nervous System Channelopathies: Pathogenesis & Treatment
    ROBERT GRIGGS; Fiscal Year: 2004
    ..They may also offer a window for understanding common disorders likely to be caused by CNS channel mutations/dysfunction such as migraine and epilepsy. ..
  12. Nervous System Channelopathies: Pathogenesis & Treatment
    ROBERT GRIGGS; Fiscal Year: 2003
    ..They may also offer a window for understanding common disorders likely to be caused by CNS channel mutations/dysfunction such as migraine and epilepsy. ..
  13. Dichlorphenamide vs Acetazolamide for Periodic Paralysis
    Robert C Griggs; Fiscal Year: 2010
    ..abstract_text> ..